Concord Asset Management (Virginia)’s Bristol-Myers Squibb BMY Stock Holding History

Concord Asset Management (Virginia)’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	19,057 +83	+0.4%	+$4.77K	0.17%	94
2026 Q1	$1.15M	Sell	18,974 -345	-2%	-$20.1K	0.19%	93
2025 Q4	$1.04M	Sell	19,319 -442	-2%	-$21.3K	0.18%	98
2025 Q3	$891K	Sell	19,761 -3,330	-14%	-$156K	0.16%	103
2025 Q2	$1.07M	Buy	23,091 +7,532	+48%	+$370K	0.16%	127
2025 Q1	$755K	Buy	15,559 +1,022	+7%	+$59.6K	0.17%	104
2024 Q4	$822K	Buy	+14,537	New	+$812K	0.18%	88
2024 Q1	–	Sell	-25,353	Closed	-$1.3M	–	135
2023 Q4	$1.3M	Buy	25,353 +9,738	+62%	+$511K	0.38%	60
2023 Q3	$906K	Buy	15,615 +2,967	+23%	+$182K	0.3%	54
2023 Q2	$809K	Buy	12,648 +2,330	+23%	+$156K	0.29%	49
2023 Q1	$715K	Buy	10,318 +6,911	+203%	+$487K	0.29%	45
2022 Q4	$245K	Buy	+3,407	New	+$257K	0.17%	48

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Concord Asset Management (Virginia)'s BMY Position: Q2 2026 in Review

Concord Asset Management (Virginia) increased its Bristol-Myers Squibb (BMY) stake by 0.44% in Q2 2026, buying an estimated $4.77K and bringing the position to 19,057 shares worth $1.1M. The position accounts for 0.17% of the portfolio, ranked #94.

Concord Asset Management (Virginia) first reported a position in BMY in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.3M in Q4 2023. 890 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Concord Asset Management (Virginia) held 19,057 shares of Bristol-Myers Squibb worth $1.1M as of Q2 2026.
Concord Asset Management (Virginia) bought 83 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.77K.
Bristol-Myers Squibb made up 0.17% of Concord Asset Management (Virginia)'s portfolio in Q2 2026, its #94 holding.
Concord Asset Management (Virginia) first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 12 quarters since.
Concord Asset Management (Virginia)'s Bristol-Myers Squibb position peaked at $1.3M in Q4 2023.
890 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Concord Asset Management (Virginia)'s 13F filing for Q2 2026, filed 27 Jul 2026.